Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...

Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

Sens. Bernie Sanders (I., Vt.) and Angus King (I., Maine) plan to introduce a bill Thursday that would ban pharmaceutical ...

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an ...

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug amycretin in 2026. The trials will include ...

The companies have said they will create customised AI models and agents that Novo Nordisk can use for early research and ...

Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The ...

It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...

The stock market is a place where people tend to panic when things go on sale. Instead, buy the dip on these four fabulous ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...